Boehringer Asks DC Circ. To Stay Aggrenox Doc Production
Boehringer Ingelheim Pharmaceuticals Inc. has told the D.C. Circuit it would be irreparably harmed if it were forced to give the Federal Trade Commission documents on a 2008 patent dispute settlement...To view the full article, register now.
Already a subscriber? Click here to view full article